Targeting the DNA damage response networks in disease: mechanistic insights and preclinical therapeutic potential of natural products

Abstract Natural products are increasingly described as modulators of the DNA damage response (DDR), but the field is limited by a recurring ambiguity: many reported effects reflect changes in DNA damage markers, oxidative stress, inflammation, or cell-cycle state rather than direct regulation of defined DDR targets. This distinction is critical because the same compound may damage DNA, enhance repair, suppress stress signaling, or alter cell fate depending on material type, dose, exposure context, and disease model. Here, we synthesize natural product-DDR research through an evidence-stratified framework that separates direct target or pathway modulation from indirect DDR-associated effects. We first outline the core DDR modules and then evaluate natural products across cancer, fibrosis, cardiovascular and cerebrovascular disorders, reproductive dysfunction, and aging-related conditions. Rather than treating all studies equally, we use a four-tier evidence system: Tier 1 denotes direct target engagement supported by causal or pathway-specific functional validation; Tier 2 denotes target-linked or pathway-functional evidence without complete direct-target or causal validation; Tier 3 denotes in vivo or combined in vitro–in vivo evidence for repair-capacity preservation or defined DDR-associated signaling without direct target engagement; and Tier 4 denotes in vitro, ex vivo, or predominantly marker-level evidence. Mixed-evidence studies are assigned according to the most mechanistically specific component directly demonstrated, while complementary indirect or marker-level findings remain explicitly described. This framework identifies where natural products have credible mechanistic support, where claims remain marker-level or context-dependent, and which translational barriers—pharmacokinetics, bioavailability, formulation, target exposure, safety, and drug-drug interactions—must be addressed before DDR-focused applications can advance. The review therefore reframes natural products not as uniformly safe multitarget agents, but as context-dependent chemical probes and therapeutic leads whose DDR relevance must be judged by mechanism, evidence strength, and disease setting.

Authors

Institutions

Publication Details

Journal
Archives of Pharmacal Research
Published
2026-11-13
DOI
https://doi.org/10.1007/s12272-026-01639-4
Primary Topic
DNA Repair Mechanisms
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Targeting the DNA damage response networks in disease: mechanistic insights and preclinical therapeutic potential of natural products

Liyun Song, Zhong-shan Yang, Yin‐Ying Wang, Li Li et al.
Archives of Pharmacal Research
DNA Repair Mechanisms
article

Targeting the DNA damage response networks in disease: mechanistic insights and preclinical therapeutic potential of natural products

Liyun Song, Zhong-shan Yang, Yin‐Ying Wang, Li Li, Wenyuan Li, Yong Qiu, Tian‐gang Li, Yuan-jie Fu, Shun-jing Wu, Ying Wang
article en

Abstract

Abstract Natural products are increasingly described as modulators of the DNA damage response (DDR), but the field is limited by a recurring ambiguity: many reported effects reflect changes in DNA damage markers, oxidative stress, inflammation, or cell-cycle state rather than direct regulation of defined DDR targets. This distinction is critical because the same compound may damage DNA, enhance repair, suppress stress signaling, or alter cell fate depending on material type, dose, exposure context, and disease model. Here, we synthesize natural product-DDR research through an evidence-stratified framework that separates direct target or pathway modulation from indirect DDR-associated effects. We first outline the core DDR modules and then evaluate natural products across cancer, fibrosis, cardiovascular and cerebrovascular disorders, reproductive dysfunction, and aging-related conditions. Rather than treating all studies equally, we use a four-tier evidence system: Tier 1 denotes direct target engagement supported by causal or pathway-specific functional validation; Tier 2 denotes target-linked or pathway-functional evidence without complete direct-target or causal validation; Tier 3 denotes in vivo or combined in vitro–in vivo evidence for repair-capacity preservation or defined DDR-associated signaling without direct target engagement; and Tier 4 denotes in vitro, ex vivo, or predominantly marker-level evidence. Mixed-evidence studies are assigned according to the most mechanistically specific component directly demonstrated, while complementary indirect or marker-level findings remain explicitly described. This framework identifies where natural products have credible mechanistic support, where claims remain marker-level or context-dependent, and which translational barriers—pharmacokinetics, bioavailability, formulation, target exposure, safety, and drug-drug interactions—must be addressed before DDR-focused applications can advance. The review therefore reframes natural products not as uniformly safe multitarget agents, but as context-dependent chemical probes and therapeutic leads whose DDR relevance must be judged by mechanism, evidence strength, and disease setting.

Archives of Pharmacal Research
Yunnan Provincial Department of Education (CN), Yunnan University of Traditional Chinese Medicine (CN)
DNA Repair Mechanisms
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon